BRNS

Barinthus Biotherapeutics plc

• TipRanks·05/21 10:36

  Barinthus Biotherapeutics Shareholders Approve Scheme of Arrangement

• Seeking Alpha·05/01 12:51

  Barinthus Biotherapeutics GAAP EPS of -$0.14

• TipRanks·05/01 06:00

  Analyst Flags High Risk in Barinthus Biotherapeutics’ Forward-Looking Statements and Guidance Reliability

• TipRanks·04/30 16:30

  Barinthus’ VTP-300 Hepatitis B Study Reaches Completion: What Investors Should Watch Next

• TipRanks·04/22 21:35

  Barinthus Biotherapeutics appoints Douglas Swirsky as CFO

• TipRanks·03/31 23:50

  Barinthus Biotherapeutics Announces Upcoming Accounting Leadership Change

• TipRanks·03/16 10:20

  Wall Street Analysts Are Bullish on Top Healthcare Picks

• Seeking Alpha·03/13 19:14

  Barinthus Biotherapeutics GAAP EPS of -$1.64

• TipRanks·03/13 12:28

  Barinthus Bio Announces 2025 Results and Clywedog Merger

• TipRanks·03/13 12:08

  Barinthus Biotherapeutics reports FY25 EPS ($1.64) vs ($1.55) last year

• TipRanks·02/23 11:32

  Barinthus Biotherapeutics Amends Cross-Border Merger Agreement Terms

• TipRanks·01/06 21:31

  Barinthus Biotherapeutics Receives Nasdaq Minimum Bid Price Notice

• NASDAQ·12/15/2025 17:00

  Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Buy: What Does It Mean for the Stock?

• TipRanks·12/11/2025 11:16

  Promising Clinical Trial Results and Strategic Merger Drive Buy Rating for Barinthus Biotherapeutics

• TipRanks·12/10/2025 13:28

  Barinthus Biotherapeutics Updates on AVALON Trial Progress